Alcohol Use Disorder - Epidemiology forecast- 2030

DelveInsight’s ‘Alcohol Use Disorder- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Alcohol Use Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Alcohol Use Disorder: Understanding

The DelveInsight’s Alcohol Use Disorder epidemiology report gives a thorough understanding of Alcohol Use Disorder by including details such as disease definition, etiology, pathophysiology, biomarkers and diagnosis. It also provides treatment algorithms and treatment guidelines for Alcohol Use Disorder in the US and Europe. Moreover, the report covers detailed information on the Alcohol Use Disorder epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:

This section encompassing Alcohol Use Disorder epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Alcohol Use Disorder epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Alcohol Use Disorder epidemiology covered in the report provides historical as well as forecasted Alcohol Use Disorder epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:
• The Alcohol Use Disorder report covers a detailed overview explaining its etiology, neurobiology classification, diagnosis and treatment patterns
• The Alcohol Use Disorder report and model provide an overview of the global trends of Alcohol Use Disorder in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Alcohol Use Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Alcohol Use Disorder.
• The report provides the segmentation of the Alcohol Use Disorder epidemiology

Report Highlights:
• 11-year Forecast of Alcohol Use Disorder Epidemiology
• 7MM Coverage
• Diagnosed Prevalence of Alcohol Use Disorder
• Gender-Specific Prevalence of Alcohol Use Disorder
• Diagnosed Prevalence of Alcohol Use Disorder by Types

KOL Views:

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to Alcohol Use Disorder?
• What are the key findings pertaining to the Alcohol Use Disorder epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Alcohol Use Disorder across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden, and unmet needs of Alcohol Use Disorder?
• What are the currently available treatments of Alcohol Use Disorder?

Reasons to buy:
The Alcohol Use Disorder Epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global Alcohol Use Disorder market.
• Quantify patient populations in the global Alcohol Use Disorder market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Alcohol Use Disorder therapeutics in each of the markets covered
• Understand the magnitude of Alcohol Use Disorder population by its epidemiology
• The Alcohol Use Disorder Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments:
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1 Key Insights
2 Executive Summary of Alcohol Use Disorder (AUD)
3 SWOT Analysis for Alcohol Use Disorder (AUD)
4 Alcohol Use Disorder (AUD) Market Overview at a Glance
4.1 Market Share (%) Distribution of AUD in 2017
4.2 Market Share (%) Distribution of AUD in 2030
5 Disease Background and Overview
5.1 Introduction
5.2 Definitions
5.3 Causes and risk factors
5.4 Subtypes of Alcoholics
5.5 Pathophysiology
5.6 Genetics of AUD
5.7 Diagnosis
5.8 Biomarkers
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Diagnosed Prevalent Population of Alcohol Use Disorder (AUD)
7 Country Wise-Epidemiology of Alcohol Use Disorder
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States
7.1.4 Diagnosed Prevalence of AUD by Types in the United States
7.2 EU-5
7.2.1 Assumptions and Rationale
7.2.2 Germany
7.2.3 France
7.2.4 Italy
7.2.5 Spain
7.2.6 United Kingdom
7.3 Japan
7.3.1 Assumptions and Rationale
7.3.2 Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.3 Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan
7.3.4 Diagnosed Prevalence of AUD by Types in Japan
8 Treatment of AUD
8.1 Guidelines
American Psychiatric Association Guidelines
NICE Guidelines
8.2 Case study: Naltrexone for the Management of Alcohol Dependence
8.3 Patient Journey
9 Unmet Needs
10 Appendix
10.1 Report Methodology
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
Table 1: Summary of Alcohol Use Disorder Market, Epidemiology, and Key Events (2017–2030)
Table 2: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017–2030)
Table 3: Prevalence of Alcohol Use Disorder (AUD) in the United States (2017–2030)
Table 4: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017–2030)
Table 5: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in the United States (2017–2030)
Table 6: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Germany (2017–2030)
Table 7: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017–2030)
Table 8: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017–2030)
Table 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in France (2017–2030)
Table 10: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017–2030)
Table 11: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017–2030)
Table 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Italy (2017–2030)
Table 13: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017–2030)
Table 14: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017–2030)
Table 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) in Spain (2017–2030)
Table 16: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017–2030)
Table 17: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017–2030)
Table 18: Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017–2030)
Table 19: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017–2030)
Table 20: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017–2030)
Table 21: Prevalence of Alcohol Use Disorder (AUD) in Japan (2017–2030)
Table 22: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017–2030)
Table 23: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017–2030)
Figure 1: SWOT Analysis
Figure 2: Natural history of alcohol use disorders
Figure 3: Neuroimmune contributions to the cycle of addiction
Figure 4: Neuron-glia cell–cell interactions in neuroimmune responses to alcohol
Figure 5: AUDIT-C questionnaire
Figure 6: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017–2030)
Figure 7: Diagnosed Prevalence of AUD in the United States (2017–2030)
Figure 8: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017–2030)
Figure 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by type in the United States (2017–2030)
Figure 10: Diagnosed Prevalence of AUD in Germany (2017–2030)
Figure 11: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017–2030)
Figure 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017–2030)
Figure 13: Diagnosed Prevalence of AUD in France (2017–2030)
Figure 14: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017–2030)
Figure 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017–2030)
Figure 16: Diagnosed Prevalence of AUD in Italy (2017–2030)
Figure 17: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017–2030)
Figure 18: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017–2030)
Figure 19: Diagnosed Prevalence of AUD in Spain (2017–2030)
Figure 20: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017–2030)
Figure 21: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017–2030)
Figure 22: Diagnosed Prevalence of AUD in United Kingdom (2017–2030)
Figure 23: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017–2030)
Figure 24: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017–2030)
Figure 25: Diagnosed Prevalence of AUD in Japan (2017–2030)
Figure 26: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017–2030)
Figure 27: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017–2030)
Figure 28: Summary of available psychological treatments for AUD
Figure 29: Patient journey for Alcohol Use Disorder
Figure 30 Unmet needs for Alcohol Use Disorder
Figure 1: SWOT Analysis
Figure 2: Natural history of alcohol use disorders
Figure 3: Neuroimmune contributions to the cycle of addiction
Figure 4: Neuron-glia cell–cell interactions in neuroimmune responses to alcohol
Figure 5: AUDIT-C questionnaire
Figure 6: Diagnosed Prevalent Population of Alcohol Use Disorder (AUD) in 7MM (2017–2030)
Figure 7: Diagnosed Prevalence of AUD in the United States (2017–2030)
Figure 8: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in the United States (2017–2030)
Figure 9: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by type in the United States (2017–2030)
Figure 10: Diagnosed Prevalence of AUD in Germany (2017–2030)
Figure 11: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Germany (2017–2030)
Figure 12: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Germany (2017–2030)
Figure 13: Diagnosed Prevalence of AUD in France (2017–2030)
Figure 14: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in France (2017–2030)
Figure 15: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in France (2017–2030)
Figure 16: Diagnosed Prevalence of AUD in Italy (2017–2030)
Figure 17: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Italy (2017–2030)
Figure 18: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Italy (2017–2030)
Figure 19: Diagnosed Prevalence of AUD in Spain (2017–2030)
Figure 20: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Spain (2017–2030)
Figure 21: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Spain (2017–2030)
Figure 22: Diagnosed Prevalence of AUD in United Kingdom (2017–2030)
Figure 23: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in United Kingdom (2017–2030)
Figure 24: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in United Kingdom (2017–2030)
Figure 25: Diagnosed Prevalence of AUD in Japan (2017–2030)
Figure 26: Gender-specific Prevalence of Alcohol Use Disorder (AUD) in Japan (2017–2030)
Figure 27: Diagnosed Prevalence of Alcohol Use Disorder (AUD) by types in Japan (2017–2030)
Figure 28: Summary of available psychological treatments for AUD
Figure 29: Patient journey for Alcohol Use Disorder
Figure 30 Unmet needs for Alcohol Use Disorder

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook